Findings on pancreatic cancer could improve immunotherapies
Researchers have revealed the immune landscape and microbiome of pancreatic cysts as they progress to pancreatic cancer, providing targets for immunotherapy.
List view / Grid view
Oncology is a branch of medicine that deals with the prevention, diagnosis and treatment of cancer.
Researchers have revealed the immune landscape and microbiome of pancreatic cysts as they progress to pancreatic cancer, providing targets for immunotherapy.
Scientists have discovered adenosine could inhibit CD39, a molecule that suppresses the immune system.
Researchers have discovered a way to ignite T cells, potentially increasing the scope and success of T cell-based immunotherapy.
Scientists have found that unconventional T cells migrate from tissue into the lymph nodes and influence immune responses there.
An animal study has shown that a modified vaccine for tuberculosis could treat bladder cancer whilst minimising side effects.
Researchers found that fibroblasts had varying effects on tumour cells based on both the type of non-small cell lung cancer and the drug used for treatment.
Researchers have developed an mRNA-based cancer vaccine that is delivered directly into the lymphatic system for a more potent response.
The researchers identified key molecular differences between triple-negative breast cancer cells that cling to an initial tumour and those that venture off to form distant tumours.
The monoclonal antibody 19A11 binds E-cadherin, a protein that helps cells stick together, especially in epithelial layers that line the skin, the gut and other organs.
New study has demonstrated that mice deficient in dendritic cell immunoreceptor are resilient against colitis and colonic tumour growth.
A T-cell bispecific antibody shows potent anti-tumour activity in preclinical models of epidermal growth factor receptor variant III (EGFRvIII) mutant glioblastoma.
Researchers analysed the expression of long non-coding RNAs in samples from patients and tumour cell lines, identifying a group of genes with augmented expression in pancreatic cancer.
F-star Therapeutics has announced a licence agreement with Takeda for a novel next-generation immuno-oncology bispecific antibody.
The scientists say that shutting down the EBAG9 gene allows the body to destroy tumour cells earlier and more radically.
Researchers have identified an important gene that could enable more targeted treatment for cancer.